{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:34:51Z","timestamp":1793763291737,"version":"4.6.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.annonc.2021.09.005","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T04:03:03Z","timestamp":1632196983000},"page":"20-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":591,"title":["Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"33","author":[{"given":"P.G.","family":"Casali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bielack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.M.G.","family":"Bovee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brodowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De \u00c1lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.G.","family":"Del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fedenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Frezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gasperoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kopeckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Kr\u00e1korov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Le Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Legius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez-Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Piana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sbaraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Scheipl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Sundby","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Frebourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.09.005_bib1","series-title":"Soft Tissue and Bone Tumours","year":"2020"},{"issue":"11","key":"10.1016\/j.annonc.2021.09.005_bib2","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/cncr.20862","article-title":"Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era \u2013 a population-based study in western Sweden","volume":"103","author":"Nilsson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2021.09.005_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"10.1016\/j.annonc.2021.09.005_bib5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/bjs.10809","article-title":"Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era","volume":"105","author":"van der Graaf","year":"2018","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.hoc.2008.11.005","article-title":"Pediatric gastrointestinal stromal tumors","volume":"23","author":"Pappo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PAS.0b013e3181c20f4f","article-title":"Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases","volume":"34","author":"Zhang","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/modpathol.2010.185","article-title":"SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors","volume":"24","author":"Gaal","year":"2011","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","article-title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD","volume":"16","author":"Pasini","year":"2008","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.pas.0000176433.81079.bd","article-title":"Gastrointestinal stromal tumors\u00a0in patients with neurofibromatosis 1: a clinicopathologic and\u00a0molecular genetic study of 45 cases","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/gast.2001.20880","article-title":"Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene","volume":"120","author":"Maeyama","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annonc.2021.09.005_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2018.02.014","article-title":"Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype","volume":"76","author":"Manley","year":"2018","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5858\/134.2.165","article-title":"Protocol for the examination of specimens from patients with gastrointestinal stromal tumor","volume":"134","author":"Rubin","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2559.2010.03624.x","article-title":"DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours","volume":"57","author":"Novelli","year":"2010","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.4677","article-title":"Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST","volume":"238","author":"Brenca","year":"2016","journal-title":"J\u00a0Pathol"},{"issue":"7","key":"10.1016\/j.annonc.2021.09.005_bib16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/PAS.0000000000000418","article-title":"KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study","volume":"39","author":"Rossi","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"10.1016\/j.annonc.2021.09.005_bib17","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1158\/1078-0432.CCR-14-1677","article-title":"Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST","volume":"20","author":"Wozniak","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2021.09.005_bib18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis","volume":"130","author":"Miettinen","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"issue":"11","key":"10.1016\/j.annonc.2021.09.005_bib20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","article-title":"Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis","volume":"10","author":"Gold","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.09.005_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.09.005_bib22","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1097\/PAS.0b013e31822d63a7","article-title":"Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables","volume":"35","author":"Rossi","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.annonc.2021.09.005_bib23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.crad.2019.06.015","article-title":"Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for Rare Adult Solid Cancers","volume":"74","author":"Alessandrino","year":"2019","journal-title":"Clin Radiol"},{"issue":"14","key":"10.1016\/j.annonc.2021.09.005_bib24","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0959-8049(03)00073-X","article-title":"18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)","volume":"39","author":"Stroobants","year":"2003","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2021.09.005_bib25","first-page":"5031","article-title":"Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor","volume":"33","author":"Ohtani","year":"2013","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2021.09.005_bib26","doi-asserted-by":"crossref","first-page":"e200397","DOI":"10.1001\/jamasurg.2020.0397","article-title":"Quality of surgery and outcome in localized gastrointestinal stromal tumors treated within an international intergroup randomized clinical trial of adjuvant imatinib","volume":"155","author":"Gronchi","year":"2020","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.annonc.2021.09.005_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial","volume":"34","author":"Joensuu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"9669","key":"10.1016\/j.annonc.2021.09.005_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.annonc.2021.01.004","volume":"32","author":"Casali","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.09.005_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ejca.2009.02.009","volume":"45","author":"Gronchi","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.09.005_bib31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jamaoncol.2016.5751","article-title":"Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial","volume":"3","author":"Joensuu","year":"2017","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2021.09.005_bib32","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","article-title":"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial","volume":"32","author":"Corless","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.09.005_bib33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.annonc.2021.09.005_bib34","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"Heinrich","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2021.09.005_bib35","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.09.005_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/bjs.10104","article-title":"Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine","volume":"103","author":"H\u00f8lmebakk","year":"2016","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib37","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1002\/bjs.10743","article-title":"Genotype and risk of tumour rupture in gastrointestinal stromal tumour","volume":"105","author":"Boye","year":"2018","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.annonc.2021.09.005_bib38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1245\/s10434-018-6353-5","article-title":"Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study","volume":"25","author":"H\u00f8lmebakk","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.09.005_bib39","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/bjs.7222","article-title":"Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour","volume":"97","author":"Hohenberger","year":"2010","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.annonc.2021.09.005_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg","year":"2009","journal-title":"J\u00a0Surg Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.09.005_bib41","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","article-title":"Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience","volume":"20","author":"Rutkowski","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.09.005_bib42","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients","volume":"28","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9440","key":"10.1016\/j.annonc.2021.09.005_bib45","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2021.09.005_bib46","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.117.196642","article-title":"Early evaluation of response using 18 F-FDG PET influences management in gastrointestinal stromal tumor patients treated with neoadjuvant imatinib","volume":"59","author":"Farag","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.annonc.2021.09.005_bib48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.09.005_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/pbc.21909","article-title":"Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib","volume":"52","author":"Janeway","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2021.09.005_bib50","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/cncr.11875","article-title":"A\u00a0two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas","volume":"98","author":"Trent","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2021.09.005_bib51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2021.09.005_bib52","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A\u00a0framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib53","doi-asserted-by":"crossref","first-page":"310","DOI":"10.18632\/oncotarget.864","article-title":"BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance","volume":"4","author":"Falchook","year":"2013","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.annonc.2021.09.005_bib54","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","article-title":"Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial","volume":"11","author":"Le Cesne","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/annonc\/mdp310","article-title":"Post-imatinib surgery in advanced\/metastatic GIST: is it worthwhile in all patients?","volume":"21","author":"Mussi","year":"2010","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2021.09.005_bib56","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib57","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1245\/s10434-011-2190-5","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132","volume":"19","author":"Wang","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.09.005_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","article-title":"Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib \u2013 analysis of prognostic factors (EORTC-STBSG collaborative study)","volume":"40","author":"Bauer","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.09.005_bib59","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ejca.2014.03.280","article-title":"Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China","volume":"50","author":"Du","year":"2014","journal-title":"Eur J Cancer"},{"issue":"9544","key":"10.1016\/j.annonc.2021.09.005_bib60","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.annonc.2021.09.005_bib61","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"issue":"9863","key":"10.1016\/j.annonc.2021.09.005_bib62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.annonc.2021.09.005_bib63","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.09.005_bib64","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1470-2045(13)70453-4","article-title":"Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial","volume":"14","author":"Kang","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.09.005_bib65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","article-title":"Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.09.005_bib66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.04.021","volume":"134","author":"Sch\u00f6ffski","year":"2020","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.annonc.2021.09.005_bib67","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2021.09.005_bib68","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1200\/JCO.2008.21.3330","article-title":"Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial","volume":"27","author":"Le Cesne","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.09.005_bib69","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1148\/radiol.2353040332","article-title":"Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate","volume":"235","author":"Shankar","year":"2005","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.annonc.2021.09.005_bib70","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.ejca.2015.05.009","article-title":"Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery","volume":"51","author":"Joensuu","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.09.005_bib71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.03.025","article-title":"Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour","volume":"78","author":"D'Ambrosio","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.09.005_bib72","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.09.005_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342104480X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342104480X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:55Z","timestamp":1760335675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342104480X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S092375342104480X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.09.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}